Strategic partnerships Leverage YMC America's acquisitions of LEWA Bioprocess Group and ChromaCon AG to position as a one-stop shop for continuous chromatography and downstream processing solutions, offering integrated systems, services, and licensing opportunities to biopharma manufacturers seeking streamlined vendors.

Analytical and process scale Target mid to large biopharma and CROs requiring both analytical columns and process chromatography systems (LPLC/HPLC, SMB) with GMP compliance and ISO 9001:2015 QMS, emphasizing productivity gains, reproducibility, and flexible customization.

Global field support Highlight alliances with field service experts like ATG and a global footprint to reassure potential customers of after-sales service, maintenance, and rapid support across major geographies, reducing operational risk for scale-up projects.

Innovative capabilities Promote N-Rich lab service expansion and advanced chromatography technologies (YMC-Triart Bio C18, YMC-SEC MAB, Chiral ART Amylose-C Neo) as differentiators for impurity profiling, biotherapeutic purification, and chiral separations.

Expansion & presence Pursue opportunities near Massachusetts and other major biotech hubs by underscoring recent office expansion, proximity to PDM/biopharma clusters, and ongoing conference presence (ASMS, Pittcon) to build relationships with potential customers and decision-makers.